Divis Laboratories Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tnwacisvdy5g1jw19b114cro.pdf

Key Takeaways


Generic Business: Pricing vs. Volume

Nilima Prasad Divi: "It is very hard to answer that particular question, but that is the hope that in the next six months to a year, we should see at least some stability with respect to the pricing pressure."

Custom Synthesis & the Peptide Opportunity

Dr. Kiran S. Divi: "We are not looking at the generic side. So, we are not producing different octamers or different decamers or APIs and keeping it ready. We are strictly looking it as a CS business at this point."

Expansion Projects & Capex


Contrast Media & Future Generics

Dr. Kiran S. Divi: "we have the six growth engines in place, right from our existing business generic products which we are maintaining them quite stable and then increasing it in growth in terms of volume, we also have our Sartan business, which is growing steadily. Our future generics, which are ready to be launched from 2026 and we are undergoing various stage of qualifications with our customers and we are gearing up a launch from 2026, some are going to be launched in '27-28 all the way to '29."

Supply Chain & Margin Levers


Guidance & Commitments

CommitmentSpecificsTimeline
Unit-III production startPhase-wise production beginning with one blockDecember 2024
Unit-III Phase-I full utilizationBackward integration initially while awaiting regulatory approvalsNext 6-7 months
Continuous flow chemistry commercial scaleExpand from pilot to commercial productionNext 1-2 years
Future generics launchesPipeline advancing through customer qualifications and regulatory approvalsStarting 2026, through 2029
Capex next yearSlightly lower than this year, brownfield expansion, barring a huge opportunityFY26

Key Metrics

MetricQ2 FY25
Consolidated total income₹2,444 cr, vs ₹1,995 cr YoY and ₹2,197 cr QoQ
Profit before tax₹722 cr, vs ₹469 cr YoY
Profit after tax₹510 cr, vs ₹348 cr YoY
Material consumption~41% of sales revenue for H1 FY25, vs 40% in Q1 FY25
Constant currency growth (H1)21%
Exports share (H1)~87% of total sales revenue
Europe and US combined export share (H1)~71% of total sales revenue
Product mix: generics vs custom synthesis (H1)49% and 51% respectively
Nutraceutical business revenue (H1)₹406 cr
Forex gain (H1)₹28 cr, vs ₹14 cr YoY
Generic business volume growthDouble digit
Contrast media volume growth outlook20% to 30% year-on-year
CAPEX guidance for FY25~₹1,600 cr (including Kakinada)
Capital work-in-progress₹1,316 cr as of Sep 30, 2024, of which Kakinada project accounts for ₹1,006 cr
Total spent on Kakinada project₹1,181 cr till Sep 30, 2024
Cash on books₹3,602 cr as of Sep 30, 2024
Receivables₹2,181 cr as of Sep 30, 2024
Inventories₹3,145 cr as of Sep 30, 2024
Transit times~70 days, extended from ~45 days due to Red Sea disruptions